Response to Comments: DL40022 MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This document is a response to public comments on MolDX Local Coverage Determination DL40022 concerning non-next generation sequencing (non-NGS) tests for diagnosis of BCR-ABL negative myeloproliferative neoplasms. The comment period ran from 08/01/2024 to 09/15/2024; the notice period begins 07/03/2025 and the policy becomes effective 08/17/2025. The content provided is administrative (timeline and receipt of comments) and does not itself specify coverage, clinical indications, exclusions, documentation, or frequency limits.